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Introduction: Thymoma is a rare and unique tumor with a long natural 
history that makes it difficult to study. Consequently, there is a dearth 
of prospective diagnostic or therapeutic clinical trials. To our knowl-
edge, there has not been an analysis of conditional survival of thy-
moma in the literature. The specific aim of this study was to study the 
5-year conditional survivals of a large population of thymoma patients.
Methods: Cases of thymoma were extracted from the Surveillance, 
Epidemiology, and End Results registry (1973–2011) and catego-
rized into Masaoka–Koga stage groupings. The primary outcomes 
compared overall survival (OS), cause specific survival (CSS), and 
5-year conditional OS and CSS, by stage. OS and CSS were calcu-
lated using the Kaplan–Meier method with the log-rank test for sig-
nificance using SAS v9.3. Conditional survival was the probability 
of surviving an additional 5 years at any point in follow-up, and used 
analysis of variance to test significance.
Results: A total of 2182 patients met inclusion criteria and were 
categorized as Masaoka–Koga stage groupings of I and IIA (“local-
ized,” 24%), IIB (“regional,” 16%), III and IV (“distant,” 50%), and 
unknown (10%). Median age was 56 (18–91), and 53% were male. 
Earlier stages had better OS (p < 0.0001) and CSS (p < 0.0001). 
Twenty-year OS for local, regional, and distant stages were 42%, 
30%, and 18%, respectively. Conditional survivals remained largely 
unchanged throughout follow-up.
Conclusions: Conditional survival provides more relevant survival esti-
mates for patients during follow-up. Further studies should investigate 
the possibility that thymoma should be considered a chronic disease.
Key Words: Thymoma, Conditional survival, SEER, Cancer 
survivorship
(J Thorac Oncol. 2015;10: 701–707)
Thymoma is a slow-growing tumor of the thymus, unique in its “benign” histology but potential for locally invasive or 
“malignant” behavior. Because all thymomas have malignant 
potential, they are not classified as benign or malignant types. 
Instead, they are divided into noninvasive and invasive forms 
for prognostic purposes. Its reported incidence is only 0.15 
per 100,000 person-years.1 This extremely rare tumor has an 
unusually long natural history. It is also unique in that it is a 
tumor that does not have an official American Joint Committee 
on Cancer or Union Internationale Contre le Cancer staging 
system, though many staging systems have been proposed for 
thymoma over the years since as early as 1978 by Bergh et al.2 
But very few of these have received clinical validation.3 The 
staging system proposed by Masaoka et al.4 in 1981 follows 
the natural history of thymoma, which initially grows locally, 
then infiltrates, disseminates, and metastasizes. Masaoka 
staging is based on the degree of invasion into surrounding 
organs. The International Thymic Malignancy Interest Group 
has formally selected the Masaoka–Koga staging system, the 
Koga modification of Masaoka staging, at least until a sci-
entifically validated system is defined in the next edition of 
their staging manuals in 2017.5 A collaborative effort by the 
International Association for the Study of Lung Cancer and 
the International Thymic Malignancy Interest Group is cur-
rently in the process of developing proposals for an official 
staging classification for thymic malignancies.6 This is the 
staging system that is most often used clinically internation-
ally and in the United States.
The rarity of thymoma makes both prospective and 
retrospective single-institution or multi-institution studies 
difficult, and the lack of an official staging system makes meta-
analysis or combination of multiple data sources difficult. The 
Surveillance, Epidemiology, and End Results (SEER) registry, 
though imperfect, is a valuable source of data on rare tumors, 
such as thymoma. A population-based cancer registry that 
covers approximately 28% of the US population, the SEER 
registry is broadly representative of the US population. It is 
the largest domestic cancer registry and has multiple quality 
control measures that have made it an international standard 
of high quality cancer registries.7 Though the SEER registry 
does not record information on American Joint Committee 
on Cancer stage, as it does for most other types of cancer, or 
Masaoka stage, it does have enough information on extent of 
disease that has been used effectively by Fernandes et al.8 to 
categorize cases into Masaoka–Koga stage groupings.
No previous study in the literature has examined condi-
tional survival of thymoma. Given the long natural history of 
thymoma, with overall survival (OS) reported not for 5-years but 
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in the range of 10 or even 20 years, conditional survival is partic-
ularly useful. Survival is an estimate of the probability of being 
alive after a period of time. The quality of statistical probabilities 
depends on the information used in the calculations. Conditional 
survival is an application of conditional probability in statistics. 
It is different from traditional survival times because it takes 
advantage of the additional information: that the patient has 
already survived for some period of time. Conditional survival 
can provide a more direct answer to patients’ question, such as 
“Now that I’m 10 years out from diagnosis, what’s my expected 
survival for another 5 years?” This is not the same as the initial 
15-year survival after diagnosis, even though 10 + 5 years is 15 
years, because the 15-year estimate could not have known that 
this patient would live for at least 10 years. This is a question 
best answered as 5-year conditional survival at 10 years.
This study was designed to examine the conditional sur-
vival of thymoma in a large group of patients from the SEER 
database. Both OS and cause specific survival (CSS) are used 
in the study of conditional survivals.
MATERIALS AND METHODS
Data were extracted from the SEER database17 for 
cases of malignant thymoma diagnosed between 1973 and 
2011. The SEER registry only collects data on “malignant” 
thymomas.1 Cases of thymoma excluding thymic carcinoma 
were identified by histology (International Classification of 
Diseases codes 8580–8585) and organ of origin (collabora-
tive stage [CS] schema). Cases were excluded if the primary 
reporting source was autopsy, death certificate, or nursing 
home or hospice; preferred primary reporting source was hos-
pital inpatient data. Patients were also excluded if they were 
diagnosed before age 18. Cases had to have been diagnosed 
with microscopic confirmation, by histology or cytology. 
Finally, inclusion required thymoma diagnosis as the first and 
only malignancy, to use cancer specific survival as CSS.
Masaoka–Koga staging was approximated using an 
approach modeled after that used by Fernandes et al.8 in 
their study of the role of radiation therapy in thymoma using 
SEER data. Cases were categorized into four stage groupings 
(Table 1): I to IIA (“invasive tumor confined to gland of ori-
gin” or “localized, not otherwise specified”), IIB (“adjacent 
connective tissue”), III to IV (“adjacent organs/structures” or 
“further contiguous extension” or any positive lymph nodes), 
and unknown (unknown extent of disease). These four stage 
groupings may be loosely referred to as “localized,” “regional,” 
“distant,” and “unknown” for the remainder of this discussion. 
If no positive lymph nodes were indicated, then they were 
assumed to be negative and did not automatically result in an 
Unknown stage assignment.
SAS v9.3 (SAS Institute Inc., Cary, NC) was used to 
extract data, select cases, define variables, and for Kaplan–Meier 
survival analysis with log-rank tests for significance. Significance 
was set at a probability value less than 0.05. SAS was also used 
for multivariable regression using the Cox proportional hazards 
model. R v3.0.2 (R Foundation for Statistical Computing, Vienna, 
Austria) was used for creating the table of baseline demographic 
and thymoma characteristics, which compared continuous vari-
ables across stages by the analysis of variance test and categorical 
variables across stages by the χ2 test. Microsoft Excel 2010 was 
used to create the conditional survival tables.
OS was defined as the time from diagnosis until death. 
CSS was defined according to the National Cancer Institute 
as the time from diagnosis until death caused by thymoma 
(because patients with any other cancer diagnosis were 
excluded). Conditional survival is the probability of surviving 
additional time y after already surviving time x, and can be 
calculated from OS or CSS using the formula: CS(y|x) = S(x + 
y)/S(x), where S(t) is the OS or CSS at time t. This study cal-
culated 5-year conditional survival for both OS and CSS. So 
for instance, the 5-year conditional OS at 3 years is the prob-
ability of a patient who has already survived 3 years to live for 
an additional 5 years, also known as to have at least 8 years 
of OS. The 5-year conditional OS at 0 year is the same as the 
OS. OS and CSS were stratified by stage and compared across 
stages by the log-rank test for significance; 5-year conditional 
OS and 5-year conditional CSS were also stratified by stage.
RESULTS
A total of 2182 patients with thymoma were identified 
from the SEER (1973–2011) data set as meeting inclusion cri-
teria. Masaoka stage group was I and IIA in 520 (24%), IIB 
in 350 (16%), III and IV in 1096 (50%), and unknown in 216 
(10%). Patients in these stage groups were significantly differ-
ent in multiple demographic (geographic region in the United 
States) and thymoma (grade, World Health Organization type, 
maximum tumor diameter, year and method of diagnosis, type 
of treatment) characteristics, as shown in Table 2. Unknown 
stage was diagnosed earlier (p < 0.0001), with median year of 
diagnosis of 1990, compared with the other stages’ 2005, 2004, 
and 2002, and had 49% cancer death, compared with other 
TABLE 1.   Masaoka–Koga Stage Definitions, Compared with the Stage Groupings Assigned Using Tumor Information from 
SEER Data
Masaoka–Koga Staging System5 Stage Groupings from SEER Data (Adapted from Fernandes et al.8)
I: Grossly and microscopically completely encapsulated tumor “Localized”: “invasive carcinoma confined to gland of origin” or 
“localized, not otherwise specified”IIA: Microscopic transcapsular invasion
IIB: Macroscopic invasion into thymic or surrounding fatty tissue, or grossly adherent 
to but not breaking through mediastinal pleura or pericardium
“Regional”: “adjacent connective tissue”
III: Macroscopic invasion into neighboring organ (i.e., pericardium, great vessel, or lung) “Distant”: “adjacent organs/structures” or “further contiguous 
extension” or any positive lymph nodesIVA: Pleural or pericardial metastases
IVB: Lymphogenous or hematogenous metastasis
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TABLE 2.   Baseline Characteristics of Stage Groups and of the Whole Cohort
Stages I and IIA Stage IIB Stages III and IV Unknown
P value
Total
Median Range Median Range Median Range Median Range Median Range
Age at diagnosis 57 18–89 57 21–91 56 18–90 55 19–89 0.8101 56 18–91
Year of diagnosis 2005 1973–2011 2004 1973–2011 2002 1973–2011 1990 1973–2011 ≤0.0001 2003 1973–2011
Size in mm (imputed) 60 0–900 70 3–240 72 0–989 70 3–170 ≤0.0001 70 0–989
Count % Count % Count % Count % P value Count %
Gender
  Female 269 52 150 43 510 47 97 45 0.0561 1026 47
  Male 251 48 200 57 586 53 119 55 1156 53
Race
  White 353 68 232 66 711 65 155 72 0.2359 1451 67
  Black 66 13 48 14 190 17 31 14 335 15
  Asian/Pac Islander 92 18 65 19 183 17 28 13 368 17
  Other 9 2 5 1 12 1 2 1 28 1
Relationship status
  Single 83 16 62 18 200 18 36 17 0.2456 381 17
  Married 308 59 227 65 646 59 126 58 1307 60
  Separated/divorced 55 11 28 8 99 9 18 8 200 9
  Widowed 47 9 23 7 114 10 24 11 208 10
  Unknown 27 5 10 3 37 3 12 6 86 4
Region
  West 254 49 177 51 602 55 96 44 0.0002 1129 52
  Central 57 11 40 11 125 11 47 22 269 12
  Northeast 117 23 77 22 186 17 44 20 424 19
  South 92 18 56 16 183 17 29 13 360 17
Hist confirm
  Cytology/not 
otherwise specified
3 1 3 1 30 3 12 6 0.0001 48 2
  Histology 517 99 347 99 1066 97 204 94 2134 98
Grade
  Grades I and II 48 9 18 5 60 5 3 1 ≤0.0001 129 6
  Grades III and IV 17 3 9 3 80 7 9 4 115 5
  Unknown 455 88 323 92 956 87 204 94 1938 89
WHO type
  Not otherwise specified 244 47 163 47 643 59 180 83 ≤0.0001 1230 56
  A 39 8 30 9 38 3 6 3 113 5
  AB 72 14 47 13 80 7 6 3 205 9
  B1 52 10 34 10 97 9 9 3 192 9
  B2 52 10 33 9 88 8 5 2 178 8
  B3 61 12 43 12 150 14 10 5 264 12
Radbeam
  Other/not otherwise 
specified
298 57 129 37 447 41 113 52 ≤0.0001 987 45
  Beam RT 222 43 221 63 649 59 103 48 1195 55
Treatment
  No treatment 29 6 11 3 163 15 58 27 ≤0.0001 261 12
  RT 23 4 18 5 158 14 41 19 240 11
  Surgery 258 50 114 33 240 22 47 22 659 30
  Surgery + RT 199 38 202 58 486 44 56 26 943 43
  Unknown 11 2 5 1 49 4 14 6 79 4
Order
  Not both Surgery + RT 320 62 147 42 605 55 159 74 ≤0.0001 1231 56
  Surgery then RT 193 37 195 56 440 40 53 25 881 40
  Unknown 7 1 8 2 51 5 4 2 70 3
(Continued)
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groups’ 12%, 12%, and 33%. Lower stages tended to have lower 
grades and more favorable World Health Organization types.
Fifteen years of OS data (Fig. 1) were used to calcu-
late 5-year conditional OS (Fig. 2). Fifteen years of CSS 
data (Fig. 3) were used to calculate 5-year conditional CSS 
(Fig. 4). Localized and regional stages had significantly better 
OS than distant or unknown stages (p < 0.0001). The same 
pattern was true for CSS (p < 0.0001). Five-year conditional 
OS and 5-year conditional CSS were relatively stable over 
time across all stages. Conditional survivals were more simi-
lar between localized and regional stages and between distant 
and unknown stages. Five-year conditional OS ranged in 80% 
for localized stage, compared with 70% for regional, 60% for 
distant, and 50% for unknown stages. There was a slight rise 
and fall of 5-year conditional OS, peaking at 90% at 6 years. 
Five-year conditional CSS ranged in 90% for localized and 
regional stages, high 70% for distant, and 70% for unknown 
stages. There was no significant increase in conditional sur-
vivals over time, even at 10 years after diagnosis.
DISCUSSION
To our knowledge, this is the first published article to 
address conditional survival and the largest study of patients 
with malignant thymoma, including 2182 patients from the 
SEER registry (1973–2011). Patients can live for decades after 
thymoma diagnosis. Because of the indolent nature of this 
disease, conditional survival can be particularly valuable for 
patients, family, and caregivers. When the patient survives for 
more than 1 year, conditional survival quantifies the patient’s 
expected survival over time, which changes every year. After 
every additional year the patient survives, conditional survival 
provides more relevant prognostic information than the more 
often reported survival estimates. Conditional survival esti-
mates are also higher than static survival probabilities. For 
instance, CSS at 15 years for a patient with stages III and IV 
thymoma is 46%, but 5-year conditional CSS for the patient 
who has already survived to the ten year is 81%. These more 
accurate prognoses can help patients and their families emo-
tionally and psychologically. Anyone can easily understand 
5-year conditional survivals.
Conditional survival analysis can also help provide evi-
dence for determining optimal follow-up testing, frequency, and 
duration. Duration of patient surveillance is not only important 
for survivorship, treatment decisions, and ensuring adequate 
surveillance times in retrospective data, but also for planning 







  Alive 381 73 238 68 519 47 52 24 ≤0.0001 1190 55
  Cancer death 63 12 43 12 358 33 106 49 570 26
  Noncancer death 76 15 69 20 219 20 58 27 422 19
Categorical variables were compared across stage groups using the χ2 test. Continuous variables were compared across stage groups using the analysis of variance. Italics indicate 
statistically significant P values (<0.05).
RT, radiation therapy, WHO, World Health Organization.
TABLE 2.   (Continued)
Count % Count % Count % Count % P value Count %
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significant in estimating economic costs and planning time-
lines. As part of the patient-centered care approach, the ability 
to reference conditional survival helps quantify the remaining 
risk to patients and families after a specific survival period. In 
addition, examining changes in this risk over time could aid in 
the design of prospective clinical trials for thymoma.
The original staging system published by Masaoka 
et al.4 in 1981 had 65% stage I, 25% stage II, 5% stage III, 
and 5% stage IV. This does not resemble the distribution of 
Masaoka–Koga stage distributions in our study. However, our 
distribution is very similar to that by Fernandes et al.,8 which is 
expected because we used the same method of stage grouping 
with updated data (1973–2003 vs. 1973–2011). About half of 
our cases were in stage groups III and IV, whereas Masaoka’s 
original cohort was 65% stage I. It is possible that SEER cod-
ers preferentially included higher stage cases because SEER 
only includes malignant thymoma and the general confusion 
over what constitutes malignant thymoma.
Although the overall quality of the SEER registry is 
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less reliable coding because they are encountered so rarely.7 
One example of this is an absence of comment about lymph 
node status. Any positive lymph nodes were categorized as 
distant stage; but both no indication and negative lymph nodes 
were treated equivalently (as negative). A nonspecific limita-
tion of SEER data is patient migration out of SEER regions 
(although more than 25% of the US population is included in 
SEER, almost 75% is not). Finally, there is also the unavoid-
able selection bias of all retrospective studies. Though these 
limitations may have played a role in the selection of patients 
available for this analysis, we remain confident in the method 
of Masaoka–Koga stage groupings based on details available 
in the SEER data (Table 1).
We chose to include patients with unknown stage group 
because this comprised 10% of our limited cohort. It is inter-
esting that they ended up having the poorest survivals, with 
a higher rate of death from thymoma. It could be related to 
improvement in treatments and increased availability of diag-
nostic imaging techniques, such as computed tomography 
(CT) or 18-fluoro-deoxyglucose positron emission tomogra-
phy over time because the unknown group was diagnosed at 
a median 12–15 years earlier than the other stages. Historical 
data may not reflect current practices in oncology. A study of 
thymoma patients identified from the Swedish Cancer Registry 
found significant (p < 0.01) improvement in OS comparing 
cases of thymoma diagnosed in Swedish Cancer Registry in 
three time periods: 1958–1972, 1973–1987, and 1988–2004.9
Masaoka staging has been shown to be a significant 
prognostic factor of OS and CSS, which was also reflected 
in our results. Although OS is the most often reported mea-
sure of survival probability, CSS can be more meaningful for 
treatment planning because it excludes nonthymoma causes of 
death and provides more disease-specific prognosis. Localized 
and regional stage groups had better OS (p < 0.0001) and CSS 
(p < 0.0001).
Conditional survival has already been used to study 
several other types of cancer. Conditional relative survival 
of ovarian cancer improved steadily over the first 5 years of 
diagnosis across all stages.10 Stage IV ovarian cancer, with 
the poorest 5-year conditional OS, improved from 17% 
at diagnosis to 56% at 5 years, and even stage I steadily 
improved from 90% to 95% over the first 5 years.10 Rectal 
cancer showed an identical pattern of steadily increasing 
conditional OS over the first 5 years, where stage I improved 
from 73% to 74% and stage IV improved from 6% to 48%.11 
The same pattern of trends, with steady improvement over 5 
years and greatest improvement from higher stages, has been 
seen in colon cancer,12 gastric cancer,13 head and neck squa-
mous cancer,14 and non–small-cell lung cancer.15 Patients are 
often told that they are “cured” of their cancer if they survive 
for a certain number of years. This is supported by condi-
tional survival analysis in many types of cancer, as men-
tioned above. Even distantly metastatic gastric cancer, for 
instance, with 2% conditional relative survival at diagnosis, 
has after 5 years of survival a conditional relative survival of 
64% (which is better than the 61% relative survival of local-
ized gastric cancer at diagnosis).13
Note that the conditional survival analyses of these other 
cancer sites stop after 5 years of conditional survival calcula-
tions. Five-year conditional survival at 5 years actually requires 
sufficient numbers of patients to survive at least 10 years, which 
can be difficult for most cancers, especially at later stages. This 
is a marked difference for thymoma, which has a long natu-
ral history. Survival after thymoma diagnosis can regularly be 
measured in decades, unlike most other cancers. We were able 
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Over 10 years, unlike the other cancer sites, conditional 
OS and conditional CSS did not change significantly in any 
of the stage groups. However, despite the lack of improve-
ment over time, the 5-year conditional survival rates were 
still relatively high compared with other tumors especially in 
advanced stages, ranging from approximately 60% to 90% 
and 70% to 95% for conditional OS and conditional CSS, 
respectively. These results indicate that the risk of death, 
whether from thymoma or any cause, does not change sig-
nificantly over time in patients diagnosed with thymoma (or 
at least, not in the first decade after diagnosis). As prognosis 
does not improve over time, it suggests that even after 10 
years, patients are not truly “cured.” This observation could 
be interpreted to suggest that patients should continue to 
follow-up annually with their oncologist for more than 10 
years, because their risk is equivalent at diagnosis and at 10 
years after diagnosis. The National Comprehensive Cancer 
Network guidelines recommend at least 10 years of surveil-
lance because thymoma can have late recurrence. However, 
by their own acknowledgment, this recommended surveil-
lance duration has not been established by published stud-
ies.16 Perhaps, malignant thymoma should be considered as 
more of a chronic disease than as a curable cancer. Or, even 
longer follow-up is needed before the improvement in con-
ditional survival is evident. Future studies should try to con-
tinue to focus on large groups of thymoma patients with even 
longer follow-up times.
Someone could argue that as conditional survival is rel-
atively high, with survival rates close to “cured” conditional 
survival of other cancers, perhaps thymoma patients do not 
require annual chest CT (after chest CT every 6 months for 
the first 2 years). However, the results of this study do not sup-
port this argument because of the high risk of thymoma recur-
rence. Survival is likely high in part because of early detection 
of recurrences in close surveillance. Unfortunately, disease 
recurrence is not recorded in SEER data.
In summary, conditional survival can be particularly 
useful for thymoma patients. Earlier Masaoka–Koga stage 
groups had significantly better OS and CSS. Five-year condi-
tional OS and CSS did not improve over the first 10 years after 
diagnosis, suggesting thymoma may be more of a chronic dis-
ease than a curable cancer. Additional study is needed with 
follow-up times longer than 20 years.
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